Production and immunogenicity of chimeric virus-like particles containing porcine reproductive and respiratory syndrome virus GP5 protein

Vaccine

Volumn 30, Issue 49, 2012, Pages 7072-7077

  Wang, Wei ^a   Chen, Xiaochun ^b   Xue, Chunyi ^a   Du, Yichao ^a   Lv, Lishan ^a   Liu, Qiliang ^a   Li, Xiaoming ^a   Ma, Yun ^a   Shen, Huifang ^a   Cao, Yongchang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b China Institute of Veterinary Drug Control   (China)

Author keywords

Chimeric virus like particles; Immune response; Porcine reproductive and respiratory syndrome virus

Indexed keywords

MEMBRANE PROTEIN; PROTEIN GP5; PROTEIN M1; PROTEIN NA; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIVIRUS; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOPLASM; FEMALE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84869083057     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.048     Document Type: Article

References (47)

1. Benfield D.A., Nelson E., Collins J.E., Harris L., Goyal S.M., Robison D., et al. Characterization of swine infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332). J Vet Diagn Invest 1992, 4(2):127-133.
2. Albina E. Epidemiology of porcine reproductive and respiratory syndrome (PRRS): an overview. Vet Microbiol 1997, 55(1-4):309-316.
3. Meulenberg J.J., Hulst M.M., de Meijer E.J., Moonen P.L., den Besten A., de Kluyver E.P., et al. Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. Virology 1993, 192(1):62-72.
4. Weiland E., Wieczorek-Krohmer M., Kohl D., Conzelmann K.K., Weiland F. Monoclonal antibodies to the GP5 of porcine reproductive and respiratory syndrome virus are more effective in virus neutralization than monoclonal antibodies to the GP4. Vet Microbiol 1999, 66(3):171-186.
5. Plagemann P.G. The primary GP5 neutralization epitope of North American isolates of porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2004, 102(3):263-275.
6. Opriessnig T., Halbur P.G., Yoon K.J., Pogranichniy R.M., Harmon K.M., Evans R., et al. Comparison of molecular and biological characteristics of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (ingelvac PRRS MLV), the parent strain of the vaccine (ATCC VR2332), ATCC VR2385, and two recent field isolates of PRRSV. J Virol 2002, 76(23):11837-11844.
7. Nilubol D., Platt K.B., Halbur P.G., Torremorell M., Harris D.L. The effect of a killed porcine reproductive and respiratory syndrome virus (PRRSV) vaccine treatment on virus shedding in previously PRRSV infected pigs. Vet Microbiol 2004, 102(1-2):11-18.
8. Zheng Q., Chen D., Li P., Bi Z., Cao R., Zhou B., et al. Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). Virus Genes 2007, 35(3):585-595.
9. Bastos R.G., Dellagostin O.A., Barletta R.G., Doster A.R., Nelson E., Zuckermann F., et al. Immune response of pigs inoculated with Mycobacterium bovis BCG expressing a truncated form of GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 2004, 22(3-4):467-474.
10. Qiu H.J., Tian Z.J., Tong G.Z., Zhou Y.J., Ni J.Q., Luo Y.Z., et al. Protective immunity induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive and respiratory syndrome virus in piglets. Vet Immunol Immunopathol 2005, 106(3-4):309-319.
11. Jiang Y., Fang L., Xiao S., Zhang H., Pan Y., Luo R., et al. Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine 2007, 25(3):547-560.
12. Wang S., Fang L., Fan H., Jiang Y., Pan Y., Luo R., et al. Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 2007, 25(49):8220-8227.
13. Cai J., Ma Y., Li J., Yan C., Hu R., Zhang J. Construction and characterization of a recombinant canine adenovirus expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus. J Vet Med Sci 2010, 72(8):1035-1040.
14. Hu J., Ni Y., Dryman B.A., Meng X.J., Zhang C. Immunogenicity study of plant-made oral subunit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Vaccine 2012, 30(12):2068-2074.
15. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008, 38(1):114-126.
16. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8(4):435-445.
17. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol 2003, 11(9):438-444.
18. Ramqvist T., Andreasson K., Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 2007, 7(7):997-1007.
19. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9(10):1149-1176.
20. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1157-1163.
21. Li Y., Xue C., Wang L., Chen X., Chen F., Cao Y. Genomic analysis of two Chinese strains of porcine reproductive and respiratory syndrome viruses with different virulence. Virus Genes 2010, 40(3):374-381.
22. Liu Y., Ji J., Xie Q., Wang J., Shang H., Chen C., et al. Isolation and complete genomic characterization of H1N1 subtype swine influenza viruses in southern China through the 2009 pandemic. Virol J 2011, 8:129.
23. Zhao Z., Qin Y., Lai Z., Peng L., Cai X., Wang L., et al. Microbial ecology of swine farms and PRRS vaccine vaccination strategies. Vet Microbiol 2012, 155(2-4):247-256.
24. Lambert M.E., Arsenault J., Poljak Z., D'Allaire S. Epidemiological investigations in regard to porcine reproductive and respiratory syndrome (PRRS) in Quebec, Canada. Part 2. Prevalence and risk factors in breeding sites. Prev Vet Med 2012, 104(1-2):84-93.
25. Chung W.B., Chan W.H., Chaung H.C., Lien Y., Wu C.C., Huang Y.L. Real-time PCR for quantitation of porcine reproductive and respiratory syndrome virus and porcine circovirus type 2 in naturally-infected and challenged pigs. J Virol Methods 2005, 124(1-2):11-19.
26. Pol J.M., van Leengoed L.A., Stockhofe N., Kok G., Wensvoort G. Dual infections of PRRSV/influenza or PRRSV/Actinobacillus pleuropneumoniae in the respiratory tract. Vet Microbiol 1997, 55(1-4):259-264.
27. Albina E., Mesplede A., Chenut G., Le Potier M.F., Bourbao G., Le Gal S., et al. A serological survey on classical swine fever (CSF), Aujeszky's disease (AD) and porcine reproductive and respiratory syndrome (PRRS) virus infections in French wild boars from 1991 to 1998. Vet Microbiol 2000, 77(1-2):43-57.
28. Solano G.I., Segales J., Collins J.E., Molitor T.W., Pijoan C. Porcine reproductive and respiratory syndrome virus (PRRSv) interaction with Haemophilus parasuis. Vet Microbiol 1997, 55(1-4):247-257.
29. Zhao Z., Wang J., Liu P., Zhang S., Gong J., Huang X., et al. Cultivation, LD(50) determination and experimental model of Streptococcus suis serotype 2 strain HA9801. Res Vet Sci 2009, 86(2):200-205.
30. Carvalho L.F., Segales J., Pijoan C. Effect of porcine reproductive and respiratory syndrome virus on subsequent Pasteurella multocida challenge in pigs. Vet Microbiol 1997, 55(1-4):241-246.
31. Latham T., Galarza J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001, 75(13):6154-6165.
32. Barman S., Adhikary L., Chakrabarti A.K., Bernas C., Kawaoka Y., Nayak D.P. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol 2004, 78(10):5258-5269.
33. Liu C., Eichelberger M.C., Compans R.W., Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995, 69(2):1099-1106.
34. Lai J.C., Chan W.W., Kien F., Nicholls J.M., Peiris J.S., Garcia J.M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol 2010, 91(Pt 9):2322-2330.
35. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010, 84(2):1110-1123.
36. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371(9615):821-827.
37. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25(1):63-72.
38. Weber J., Cheinsong-Popov R., Callow D., Adams S., Patou G., Hodgkin K., et al. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 1995, 13(9):831-834.
39. Schodel F., Wirtz R., Peterson D., Hughes J., Warren R., Sadoff J., et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 1994, 180(3):1037-1046.
40. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005, 35(7):2031-2040.
41. Lowe J.E., Husmann R., Firkins L.D., Zuckermann F.A., Goldberg T.L. Correlation of cell-mediated immunity against porcine reproductive and respiratory syndrome virus with protection against reproductive failure in sows during outbreaks of porcine reproductive and respiratory syndrome in commercial herds. J Am Vet Med Assoc 2005, 226(10):1707-1711.
42. Zuckermann F.A., Garcia E.A., Luque I.D., Christopher-Hennings J., Doster A., Brito M., et al. Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Vet Microbiol 2007, 123(1-3):69-85.
43. Royaee A.R., Husmann R.J., Dawson H.D., Calzada-Nova G., Schnitzlein W.M., Zuckermann F.A., et al. Deciphering the involvement of innate immune factors in the development of the host response to PRRSV vaccination. Vet Immunol Immunopathol 2004, 102(3):199-216.
44. Lopez O.J., Oliveira M.F., Garcia E.A., Kwon B.J., Doster A., Osorio F.A. Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent. Clin Vaccine Immunol 2007, 14(3):269-275.
45. Lopez O.J., Osorio F.A. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol 2004, 102(3):155-163.
46. Osorio F.A., Galeota J.A., Nelson E., Brodersen B., Doster A., Wills R., et al. Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity. Virology 2002, 302(1):9-20.
47. Mateu E., Diaz I. The challenge of PRRS immunology. Vet J 2008, 177(3):345-351.